Log In
BCIQ
Print this Print this
 

NM505

  Manage Alerts
Collapse Summary General Information
Company MicroBiome Therapeutics LLC
DescriptionOral combination of metformin and a gastrointestinal microbiome modulator
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPilot
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes in patients with metformin resistance
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today